{"prompt": "['2.2', 'Trial Diagram', 'Biopsy', 'Screening', 'Allotment', 'Nephrectomy', 'Pembrolizumab + lenvatinib X 4 cycles', '(1 cycle = 21 days)', 'PRE-TREATMENT', 'TREATMENT', 'POST-', 'LONG-TERM', 'TREATMENT', 'FOLLOW UP', '3.0 OBJECTIVE(S) & HYPOTHESIS(ES)', '3.1 Primary Objective & Hypothesis', '(1) Objective: To assess the objective response rate (complete and partial responses), following', 'the administration of lenvatinib and pembrolizumab for a total of 4 cycles (12 weeks) in', 'patients with locally-advanced, biopsy-proven non-metastatic ccRCC prior to undergoing', 'nephrectomy (partial or radical).', '(2) Hypothesis: Patients with non-metastatic ccRCC who are treated with 12 weeks of', 'neoadjuvant lenvatinib with pembrolizumab will achieve an objective response rate >= 25%.', '3.2', 'Secondary Objectives', '(1) Objectives:', 'To assess the safety and tolerability of neoadjuvant lenvatinib plus pembrolizumab in', 'apresurgical population.', 'To determine the clinical outcomes including disease-free survival (DFS) and overall', 'survival (OS) of patients with non-metastatic ccRCC treated with neoadjuvant lenvatinib', 'and pembrolizumab.', 'To evaluate surgery-related complications and outcomes as per the Clavien-Dindo', 'classification system [1]', 'Page 4', 'Version Date: 05/08/2020']['3.3', 'Exploratory Objectives', '(1) Objectives:', 'To evaluate changes in biomarkers of immune activation and gene expression before,', 'during and after treatment', 'To assess the quality of life, frailty and sarcopenia of patients before and after treatment', '4.0 BACKGROUND & RATIONALE', '4.1 Background', '4.1.1 Introduction', 'In the United States in 2018, there were approximately 65,340 new cases of kidney or renal', 'pelvis cancer diagnosed with 14,970 deaths attributable to the disease [2]. Renal cell carcinomas', '(RCC) arising from the renal cortex make up about 85% of kidney cancers in adults with clear', 'cell histology making up as many as 85% of RCC [3]. Tumor pathogenesis in clear cell renal cell', 'carcinoma (ccRCC) is most often related to deletion, mutation or silencing of the von Hippel-', 'Lindau (VHL) tumor suppressor gene, either through spontaneous deletion of chromosome 3p', '(on which VHL lies) or in the autosomal dominant VHL disease [4]. When VHL is defective,', 'this leads to the accumulation of hypoxia inducible factors (HIFs) which in turn induces the', 'production of multiple factors implicated in RCC tumorigenesis including vascular endothelial', 'growth factor (VEGF), a main driver of angiogenesis. VEGF is a major molecular target in the', 'treatment of RCC in those with unresectable disease or poor surgical candidates for nephrectomy', '[5-9].', '4.1.2 Lenvatinib in RCC', 'Lenvatinib is an oral multi-kinase inhibitor of the vascular endothelial growth factor receptor', '(VEGFR 1-3), fibroblast growth factor receptor (FGFR1-4), platelet growth factor receptor a', '(PDGFR a), RET and KIT. Lenvatinib was approved by the FDA in May 2016 in combination', 'with the mTOR inhibitor everolimus in the treatment of advanced RCC based on the', 'randomized, open-label phase II trial investigating lenvatinib, everolimus or the combination of', 'the two agents (in a 1:1:1 ratio) in patients with metastatic disease who had previously received', 'at least one VEGFR inhibitor. Lenvatinib plus everolimus produced a significantly higher', 'progression-free survival (PFS) compared to everolimus alone (median 14.6 months versus 5.5', 'months). Even lenvatinib alone prolonged PFS to 7.4 months compared to everolimus alone,', 'although the difference was not as robust as when compared to the combination [10]. Overall', 'survival (OS) was a secondary endpoint and was 25.5 months for lenvatinib plus everolimus,', '18.4 months for single agent lenvatinib and 17.5 months for single agent everolimus; these', 'differences were not significant at the time of primary data cutoff. Of note, lenvatinib has an', 'acceptable safety profile and is also indicated as a single agent in the first line treatment of', 'unresectable hepatocellular carcinoma as well as differentiated thyroid carcinoma that has', 'progressed despite radioactive iodine therapy [11, 12]. Recently, combination of lenvatinib and', 'Page 5', 'Version Date: 05/08/2020']\n\n###\n\n", "completion": "END"}